SecProbe.io

CORRESP
1
filename1.htm

Akari Therapeutics, PLC

75/76 Wimpole Street

London W1G 9RT

United Kingdom

February 22, 2018

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

    Re:
    Akari Therapeutics, PLC

        Registration Statement on Form F-3

        File No. 333-220052

VIA EDGAR

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities
Act of 1933, as amended, Akari Therapeutics, PLC (the “Registrant”) hereby respectfully requests that the effectiveness
of the Registration Statement on Form F-3 (File No. 333-220052) of the Registrant (the “Registration Statement”)
be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on February 23, 2018 or as soon thereafter as
may be practicable.

The Registrant hereby confirms that it is
aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended,
as they relate to the proposed offering of the securities specified in the Registration Statement. The Registrant hereby acknowledges
that:

 · should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority,
declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration
Statement;

 · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement
effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the
filing; and

 · the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated
by the Commission or any person under the federal securities laws of the United States.

The undersigned respectfully requests that
it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will & Emery
LLP, by calling Gary Emmanuel at (917) 297-4545. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request
for acceleration.

Please also provide a copy of the Commission’s
order declaring the Registration Statement effective to Mr. Emmanuel via email to gemmanuel@mwe.com or facsimile to (212) 547-5444
and via mail at 340 Madison Avenue, New York, NY 10173.

    Very truly yours,

    AKARI THERAPEUTICS, PLC

    By:
    /s/ David Horn Solomon

    Name: David Horn Solomon

    Title: Chief Executive Officer

cc: Gary Emmanuel (McDermott Will & Emery LLP)